*Lupin Ltd* is in the process to acquire a generics company in Japan. The
target company is in the generic injectable drugs segment.

The deal value could be in the same range as its earlier acquisition of *Kyowa
Pharmaceuticals Ltd* in 2007 for $100 mn.

The deal is expected to be completed in six-eight months and would be funded
through internal accruals and debt, if required.

This acquisition will help Lupin’s presence to all potential product
segments in the Japanese market.

Lupin is exploring growth opportunities through acquisitions, joint ventures
and local alliances in product segments where it does not have a significant
market presence and is mainly looking for injectable segment to make a
strong entry in the hospital sector and this deal cold be the perfect fit
for Lupin.

This would be Lupin’s second acquisition in Japan, after Kyowa.
 Transaction Note

Headquartered in Mumbai, Lupin Limited is an innovation led transnational
pharmaceutical company producing a wide range of quality, affordable generic
and branded formulations and APIs for the developed and developing markets
of the world.

For the financial year ended March 2010, Lupin's consolidated revenues and
profit after tax were Rs.4,740.5 Cr ($1.1 bn) and Rs.681.6 Cr ($ 138 mn)
respectively.

In 2009, Lupin acquired the brand *Antara* from *Oscient
Pharmaceuticals*for $38.61 mn.

Other than Kyowa, Lupin’s past acquisitions were, *Hormosan* (Germany), *Pharma
Dynamics *(South Africa), *Generic Health *(Australia) in 2008 and *Multicare
Pharma* (Philippines) in 2009.

This year in March, *Claris Lifesciences Ltd*, the pharma major specialising
in manufacturing sterile injectables, had planned its acquisitions in Europe
and is looking for license deals.

Last year, *Hospira Inc *acquired *Orchid Chemicals & Pharmaceuticals Ltd's
*generic injectable drug business for $400 Mn and *General Atlantic *had
talks to buy around 40% stake in *Strides Arcolabs* injectibles business arm
- *Strides Specialities *for $100 Mn.

-- 
Regards

Hardik Shah

-- 
You received this message because you are subscribed to the Google Groups 
""GLOBAL SPECULATORS"" group.
To post to this group, send email to [email protected].
To unsubscribe from this group, send email to 
[email protected].
For more options, visit this group at 
http://groups.google.com/group/globalspeculators?hl=en.

Reply via email to